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Abstract 
Background: Gestational diabetes mellitus (GDM) has significant implications for the future health of the mother. 
Some clinical studies have suggested subclinical inflammation and vascular dysfunction after GDM. We aimed to 
study whether concentrations of high‑sensitivity C‑reactive protein (hsCRP), tissue inhibitor of metalloproteinase‑1 
(TIMP‑1), matrix metalloproteinase‑8 (MMP‑8) and ‑9, as well as values of arterial stiffness differ between women with 
and without a history of GDM a few years after delivery. We also investigated possible effects of obesity on the results.
Methods: We studied two cohorts—120 women with a history of GDM and 120 controls—on average 3.7 years 
after delivery. Serum concentrations of hsCRP were determined by immunonephelometric and immunoturbidi‑
metric methods, MMP‑8 by immunofluorometric assay, and MMP‑9 and TIMP‑1 by enzyme‑linked immunosorb‑
ent assays. Pulse wave velocity (PWV) was determined using the foot‑to‑foot velocity method from carotid and 
femoral waveforms by using a SphygmoCor device. Arterial compliance was measured non‑invasively by an HDI/
PulseWave™CR‑2000 arterial tonometer. All 240 women were also included in subgroup analyses to study the effect 
of obesity on the results. Multiple linear regression analyses were performed with adjustment for confounding factors.
Results: PWV after pregnancy complicated by GDM was significantly higher than after normal pregnancy, 
6.44 ± 0.83 (SD) vs. 6.17 ± 0.74 m/s (p = 0.009). Previous GDM was also one of the significant determinants of PWV 
in multiple linear regression analyses. On the other hand, compliance indices of both large (p = 0.092) and small 
(p = 0.681) arteries did not differ between the study cohorts. Serum TIMP‑1 levels were significantly increased after 
previous GDM (p = 0.020). However, no differences were found in the serum levels of MMP‑8, MMP‑9 or hsCRP. In 
subgroup analyses, there were significantly higher concentrations of hsCRP (p = 0.015) and higher PWV (p < 0.001) 
among obese women compared with non‑obese ones.
Conclusions: PWV values were significantly higher after GDM compared with normoglycemic pregnancies and were 
associated with prolonged TIMP‑1 upregulation. Cardiovascular risk factors were more common in participants with 
high BMI than in those with previous GDM.
Keywords: Arterial compliance, Gestational diabetes mellitus, High‑sensitivity C‑reactive protein, Matrix 
metalloproteinase‑8, Matrix metalloproteinase‑9, Pulse wave velocity, Subclinical inflammation, Tissue inhibitor of 
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Background
In developed countries, the prevalence of gestational 
diabetes mellitus (GDM) has increased rapidly in recent 
decades, along with increasing rates of obesity [1, 2]. In 
Finland, GDM complicated 15.9% of pregnancies in 2015 
[2]. A diagnosis of GDM has significant implications for 
the future health of the mother. For instance, GDM has 
been shown to be associated with postpartum insulin 
resistance, hypertension, and dyslipidemia [3–5], placing 
affected women at risk of metabolic syndrome (MetS), 
type 2 diabetes mellitus (T2DM) and/or cardiovascu-
lar disease (CVD) later in life [5–8]. Incidence of CVD 
events, and specifically those of coronary artery disease, 
is known to be increased in women with previous GDM, 
even in the absence of T2DM [8]. Clinical studies have 
also revealed subclinical inflammation and vascular dys-
function after GDM [4].
High-sensitivity C-reactive protein (hsCRP) is a well-
known acute-phase protein and a sensitive biomarker of 
systemic inflammation. Elevated levels of hsCRP are a 
significant risk factor for atherosclerosis [9]. The group 
of matrix metalloproteinases (MMPs) comprises over 
20 structurally and functionally related but genetically 
distinct members [10, 11]. Expression and activity are 
normally low, but increased in many pathophysiologi-
cal conditions. MMPs can modulate immunological 
responses, and MMPs can be either defensive or destruc-
tive [11]. Both upregulation and down-regulation of 
MMP-8 and -9 have been associated with several nonin-
fectious as well infectious inflammatory states [12–18]. 
MMP-8 may also regulate blood pressure [19]. MMPs 
and their inhibitors, tissue inhibitors of MMPs (TIMPs) 
have been related to atherosclerosis development and 
progression in humans [20–22]. It has been suggested 
that imbalanced concentrations of MMP family members 
and TIMPs eventually exert an important role in cardio-
vascular risk [21–25].
Inflammation may be pathogenic, by inducing vascu-
lar dysfunction [4, 26]. Arterial stiffness has proven to 
be an important parameter for the assessment of car-
diovascular risk, and it has earlier been associated with 
endothelial dysfunction [27, 28]. Carotid to femoral pulse 
wave velocity (PWV) has emerged as the gold standard to 
assess arterial stiffness [29]. When the arteries are stiff or 
less distensible, PWV increases [30, 31]. PWV increases 
proportionally to the number of cardiovascular risk fac-
tors present, such as diabetes or MetS [27, 32, 33]. In epi-
demiological studies, increased PWV has been predictive 
of cardiovascular events [29].
Recently, the implications of GDM as regards wom-
en’s future health have been widely discussed. As the 
prevalence of GDM has increased over the years, a 
better understanding of the connections between 
previous GDM and both subclinical inflammation and 
vascular dysfunction would be of great benefit. In addi-
tion, recently it has been suggested that MMP-8 is associ-
ated with insulin receptor degradation, and high serum 
MMP-8 levels with an increased risk of diabetes mellitus 
type II [17]. In previous studies serum levels of MMP-8, 
-9, TIMP-1 and hsCRP have been shown to be biomark-
ers reflecting low-grade inflammation [11, 23, 24, 34, 35]. 
In addition, TIMP-1 has been shown to exert MMP-inde-
pendent actions such as pro-inflammatory and growth-
factor-like properties [36–38].
With this background our aim was to define whether 
or not cardiovascular risk, assessed by serum concentra-
tions of hsCRP, MMP-8, MMP-9 and TIMP-1, and values 
of arterial compliance and PWV are enhanced already a 
few years after GDM. We also evaluated the effect of obe-
sity on the results.
Methods
In this follow-up study of two cohorts, a total of 120 
women with a history of GDM during the index preg-
nancy were compared with 120 age-matched women 
with normal glucose metabolism during pregnancy. The 
time from the index pregnancy to the follow-up study 
was also matched between the study groups. All par-
ticipants had delivered on average 3.7 (range 2–6) years 
earlier at Kanta-Häme Central Hospital, Finland, i.e. 
after the publication of Finnish Current Guidelines for 
screening GDM. Our national guidelines were published 
in 2008 and updated in 2013 without any change in the 
diagnostic criteria of GDM [39]. The complete inclu-
sion and exclusion criteria, with power analysis, have 
been described earlier [40]. Briefly, GDM was defined 
(using the diagnostic criteria of Finnish Current Guide-
lines) as a pathological value in a 2-h 75-g oral glucose 
tolerance test (OGTT) during pregnancy: venous plasma 
glucose ≥5.3  mmol/L when fasting, ≥10.0  mmol/L at 
1  h or ≥8.6  mmol/L at 2  h [39]. Our national diagnos-
tic thresholds for GDM are similar to those of the Inter-
national Association of Diabetes and Pregnancy Study 
Groups (IADPSG): plasma glucose ≥5.1  mmol/L when 
fasting, ≥10.0 mmol/L at 1 h or ≥8.5 mmol/L at 2 h [41]. 
Only singleton pregnancies were included. Women were 
excluded if they had type 1 or type 2 diabetes before the 
pregnancy, if they were pregnant at time of the study, if 
they had suspected or verified malignant or endocrine 
disease, if there was substance abuse or treatment, or a 
known clinical history of psychiatric illness. Controls had 
to have normal OGTT results during pregnancy. If the 
controls had experienced GDM in an earlier pregnancy, 
or the weight of the newborn was ≥4.5  kg, they were 
excluded. The electronic database of the hospital was 
used to pick up the cases and controls. Both recruitment 
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and examinations were accomplished between August 
2011 and July 2014.
We interviewed the participants as regards their life-
style habits. Lifetime tobacco exposure was estimated 
as pack-years, and one pack-year was defined as 20 
cigarettes smoked every day for 1 year [42]. Further, we 
interviewed the participants as regards their history of 
trauma or infectious diseases during the previous month. 
We measured resting heart rate, brachial blood pres-
sure, weight (kg) and height (cm) of the participants, and 
calculated body mass index (BMI): weight in kilograms 
divided by height in meters squared (kg/m2).
The study was conducted in accordance with the ethi-
cal principles outlined in the Declaration of Helsinki [43], 
and the protocol was approved by the Ethics Commit-
tee of Kanta-Häme Hospital District (reference number 
521/2010; date of approval 21.12.2010). Every participant 
was given both oral and written information on the study 
before she signed an informed consent document.
Laboratory methods
Serum samples were collected after at least 12 h of fast-
ing and stored at −80 °C until analyzed. Serum concen-
trations of hsCRP were analyzed according to validated 
immunonephelometric (United Medix Laboratories 
Ltd., Espoo, Finland) and immunoturbidimetric (VITA 
Healthcare Services Ltd., Vita Laboratory, Helsinki, 
Finland) methods [44, 45]. Concentrations of MMP-8 
were determined by immunofluorometric assay (IFMA) 
(Medix Biochemica, Espoo, Finland), as previously 
described [25]. Serum levels of MMP-9 and TIMP-1 
were analyzed by enzyme-linked immunosorbent assay 
(ELISA) using commercial kits (Biotrak ELISA System; 
Amersham Biosciences, GE Healthcare, Buckingham-
shire, UK) and according to the manufacturer’s instruc-
tions [18]. Fasting serum levels of total cholesterol (TC) 
and insulin were analyzed according to validated meth-
ods as described in detail earlier [40].
Determination of arterial compliance and pulse wave 
velocity
Three experienced nurses measured the compliance of 
large and small arteries after at least 10 min of rest in a 
semi-sitting position. The recording was carried out 
after an overnight fast. The participants were asked to 
refrain from eating, having caffeinated drinks, smoking 
and taking medication for 12 h, and drinking alcohol for 
2  days prior to measurement. Radial artery pulse waves 
were recorded non-invasively with an arterial tonom-
eter (HDI/PulseWave™CR-2000, Hypertension Diagnos-
tics, Inc., Eagan, Minnesota, USA) and the procedure 
involves the use of a modified Windkessel pulse-contour 
method [46]. Blood volume inertia and systemic vascular 
resistance are used to analyze arterial compliance. The 
capacitive compliance of large arteries (C1), including the 
aorta, and the endothelial function of small arteries (C2) 
were automatically assessed as a mean of the five most 
similar pulse waves appearing during 30-s of measure-
ment. Three consecutive measurements were performed 
to obtain mean results for every participant.
Carotid-femoral PWV was measured using the foot-
to-foot velocity method from carotid and femoral wave-
forms by employing a SphygmoCor device (AtCor 
Medical, Sydney, Australia). Transcutaneous readings 
were obtained at the right common carotid artery and the 
right femoral artery with the subjects in a supine position 
with direct-contact pulse sensors. The time delay (Dt or 
transit time) of the two waveforms was registered, and 
the distance (D) between carotid and femoral recording 
sites was obtained by subtracting the carotid measure-
ment site to sternal notch distance from the sternal notch 
to the femoral measurement site distance. PWV was cal-
culated as follows: D/Dt (m/s) [29, 30]. Three measure-
ments were performed to obtain average results for every 
participant. Only measurements that met the automatic 
quality control cutoff were used in the final analysis. All 
the PWV measurements were performed by two experi-
enced nurses.
Statistical analysis
The data were analyzed by using  IBM®  SPSS® Statistics 
Version 23 software (copyright 2015). Variables were 
tested for normality by way of Shapiro–Wilk or Kolmogo-
rov–Smirnov tests, as appropriate. Data are presented as 
mean ± standard deviation (SD) if not mentioned other-
wise. Differences in continuous variables between GDM 
participants and controls were studied by using Student’s 
t test in cases of normality and the Mann–Whitney U test 
in cases of skewed distribution of measurements.
All 240 women were also included in subgroup analy-
ses to study the effect of obesity on the results. For these 
analyses, we divided the whole study group into four sub-
groups according to obesity and previous GDM. Obe-
sity was classified as BMI ≥30  kg/m2 [47]. The clinical 
characteristics of these four subgroups were studied by 
way of one-way ANOVA in cases of normality and by 
using the Kruskal–Wallis test in cases of non-normality. 
If the overall p value was significant, individual p values 
between subgroups were also calculated. Post hoc anal-
yses, with a conservative Bonferroni correction factor, 
were performed in order to correct for multiple testing. 
The relationships between different cardiovascular risk 
factors were tested by Pearson’s or Spearman’s correla-
tion analysis, as appropriate.
Further, we conducted univariate linear regression 
analyses for hsCRP, MMP-8, TIMP-1, PWV and arterial 
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compliance index values to find possible associations 
with clinically relevant covariates. Then multivariable lin-
ear analyses were carried out to examine whether simple 
associations were changed after adjustment for potential 
confounders. Finally, stepwise multiple linear regression 
analyses were done to find out relevant covariates to final 
models. The selected covariates in all of these analyses 
were age, BMI, previous GDM, time after the index preg-
nancy, pack-years of smoking, heart rate, systolic blood 
pressure, hsCRP, TC and fasting insulin. F-statistics was 
used to optimize the sequential variable selection proce-
dure. A two-tailed probability value of <0.05 was consid-
ered significant.
Results
The basic clinical characteristics of the study participants 
are summarized in Table 1. There were no significant dif-
ferences between the two cohorts in self-reported his-
tory of respiratory infection, other infectious disease or 
trauma during the month before follow-up laboratory 
examinations.
Subclinical inflammation
Serum TIMP-1 levels were significantly increased after 
previous GDM (Table 2). There was a significant positive 
association between previous GDM and TIMP-1 levels 
in both univariate and multivariable linear regression 
analyses (data not shown). There were no differences in 
the concentrations of MMP-8 and MMP-9 between the 
groups (Table  2). In stepwise multiple linear regression 
analyses, hsCRP, previous GDM and TC were important 
determinants of MMP-8 levels. Likewise, previous GDM, 
together with BMI and heart rate associated with TIMP-1 
in stepwise multiple linear regression analyses. Neverthe-
less, the significant determinants explained only 13.8% of 
MMP-8 and 6.7% of TIMP-1 concentrations (Table 3).
We found no difference in the concentrations of hsCRP 
between GDM cases and controls (Table  2), even when 
participants affected with infections or traumas were 
excluded (data not shown). In stepwise multiple linear 
regression analysis (Table 3), only BMI was a significant 
determinant of hsCRP levels, but the model explained 
only 9.6% of hsCRP values. Previous GDM did not influ-
ence hsCRP concentrations in our data.
Pulse wave velocity and arterial compliance
PWV values differed significantly between the GDM 
cases and controls (Table 2). In univariate linear regres-
sion analysis, there were significant associations with age 
(p  <  0.001), fasting insulin (p  <  0.001), previous GDM 
(p = 0.009), TC (p < 0.001), heart rate (p < 0.001), systolic 
blood pressure (p < 0.001) and BMI (p < 0.001). In step-
wise multiple linear regression analysis, significant deter-
minants of PWV values were systolic BP, age, insulin 
levels, previous GDM and time after the index pregnancy. 
Covariates explained 47.0% of PWV (Table 3). In our two 
study cohorts, there were no interactions between previ-
ous GDM and TIMP1 on PWV (data not shown).
There was a nonsignificant difference in C1 values 
between the study groups. No difference was revealed in 
C2 values, either. In univariate linear regression analysis, 
Table 1 Basic clinical characteristics of  women with  GDM 
and controls
Data are presented as mean ± SD if not mentioned otherwise
BMI body mass index, BP blood pressure, F-Gluc fasting glucose, F-Insu fasting 
insulin, TC total cholesterol
GDM Controls p value
Average time since delivery, years 3.7 ± 1.0 3.7 ± 0.9 0.818
Age, years 35.8 ± 4.4 35.9 ± 4.6 0.854
Primiparous, n (%) 23 (19.2%) 23 (19.2%) 1.000
Therapy of GDM during pregnancy
 Insulin, n (%) 24 (20.0%)
 Metformin, n (%) 1 (0.8%)
 Dietary therapy, n (%) 95 (79.2%)
Pack‑years of smoking 3.8 ± 6.0 2.4 ± 4.6 0.012
During the previous month, history of
 Respiratory infection, n (%) 45 (37.5%) 44 (36.7%) 0.854
 Other infectious disease, n (%) 18 (15.0%) 10 (8.3%) 0.053
 Trauma, n (%) 9 (7.5%) 5 (4.2%) 0.264
BMI, kg/m2 28.3 ± 5.0 27.5 ± 5.4 0.069
Systolic BP, mmHg 122.4 ± 12.5 119.0 ± 11.5 0.034
Diastolic BP, mmHg 73.5 ± 9.0 71.8 ± 8.7 0.176
Heart rate, beats per minute 65.9 ± 9.1 63.8 ± 9.6 0.017
TC, mmol/L 4.7 ± 0.9 4.6 ± 0.8 0.329
F‑Gluc, mmol/L 5.6 ± 0.6 5.3 ± 0.3 <0.001
F‑Insu, mU/L 5.2 ± 3.6 4.6 ± 3.6 0.087
Table 2 Results of  primary analyses of  GDM and  control 
groups
Data are presented as mean ± SD
hsCRP high‑sensitivity C reactive protein, C1 large artery compliance index, 
C2 small artery compliance index, PWV pulse wave velocity, MMP-8 matrix 
metalloproteinase‑8, MMP-9 matrix metalloproteinase‑9
GDM Controls p value
hsCRP, mg/L 2.50 ± 3.69 2.50 ± 4.19 0.582
MMP‑8, ng/mL 27.83 ± 1.48 32.78 ± 1.90 0.082
MMP‑9, ng/mL 384.27 ± 13.15 392.15 ± 12.60 0.667
TIMP‑1, ng/mL 102.80 ± 29.72 94.58 ± 24.51 0.020
MMP‑8/TIMP‑1, mol ratio 0.13 ± 0.009 0.17 ± 0.015 0.035
MMP‑9/TIMP‑1, mol ratio 1.32 ± 0.078 1.43 ± 0.085 0.152
C1, mL/mmHg × 10 15.14 ± 3.51 15.85 ± 3.36 0.092
C2, mL/mmHg × 100 8.44 ± 3.08 8.60 ± 3.20 0.681
PWV, m/s 6.44 ± 0.83 6.17 ± 0.74 0.009
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there was no significant association between C2 and BMI 
(p =  0.726), but an inverse association between C1 and 
BMI was significant (p = 0.025). In stepwise multiple lin-
ear regression analysis, systolic BP, heart rate, BMI and 
time after the index pregnancy were significant covari-
ates explaining 52.4% of C1 values. Significant determi-
nants of C2 values were systolic BP, heart rate, BMI, age 
and pack-years of smoking. These covariates explained 
31.7% of C2 values (Table 3).
Effect of obesity in subgroups
Altogether, there were 75 women in the obese group 
(BMI  ≥  30  kg/m2); 43 GDM and 32 control partici-
pants. The non-obese group (BMI < 30 kg/m2; n = 165) 
consisted of 77 GDM and 88 control participants [55]. 
In subgroup analyses, participants in obese subgroups 
had higher serum concentrations of hsCRP than those 
in non-obese subgroups, as shown in Fig.  1. The con-
centrations of MMP-8 in the four subgroups were 
as follows: obese GDM cases, 27.76  ±  1.77  ng/mL, 
obese controls 37.10  ±  4.16  ng/mL, non-obese GDM 
cases, 27.88  ±  2.08  ng/mL and non-obese controls, 
31.21  ±  2.10  ng/mL. The concentration of MMP-8 
was highest among obese controls, but the differ-
ences between the four subgroups were not significant 
(p = 0.090). We also found no differences in the levels of 
MMP-9 or TIMP-1 between these four subgroups (data 
not shown). Between the subgroups, there were no dif-
ferences in the MMP-8/TIMP-1 or MMP-9/TIMP-1 ratio 
either (data not shown). In the four subgroups, differ-
ences in PWV values were significant, but differences in 
both C1 and C2 values were not (Figs. 2, 3).  
Table 3 Results of stepwise multiple linear regression analyses
Covariates in these analyses included age, BMI, previous GDM, pack‑years of smoking, time after the index pregnancy, heart rate, systolic blood pressure, hsCRP, TC 
and fasting insulin. Final models include significant covariates only. Standardized β provides a measure of the relative strength of an association, independent of the 
measurement units. Standardized β and p values are shown only when p < 0.05
BMI body mass index, BP blood pressure, F-Insu fasting insulin, GDM gestational diabetes mellitus, hsCRP high‑sensitivity C reactive protein, C1 large artery compliance 
index, C2 small artery compliance index, PWV pulse wave velocity, MMP-8 matrix metalloproteinase‑8
Parameters Covariates included  
in the model
R2 for model Global p Standardized β p value
hsCRP 0.096 <0.001
BMI 0.259 <0.001
MMP‑8 0.138 <0.001
hsCRP 0.312 <0.001
Previous GDM −0.137 0.025
TC 0.129 0.036
TIMP‑1 0.067 0.003
Previous GDM 0.157 0.015
BMI 0.149 0.025
Heart rate −0.132 0.044
C1 0.524 <0.001
Systolic BP −0.602 <0.001
Heart rate −0.347 <0.001
BMI 0.232 <0.001
Time after the index pregnancy −0.095 0.041
C2 0.317 <0.001
Systolic BP −0.345 <0.001
Heart rate −0.312 <0.001
BMI 0.286 <0.001
Age −0.191 0.001
Pack‑years of smoking −0.144 0.012
PWV 0.470 <0.001
Systolic BP 0.534 <0.001
Age 0.230 <0.001
F‑Insu 0.191 <0.001
Previous GDM 0.105 0.026
Time after the index pregnancy −0.102 0.040
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Discussion
Our main finding was that PWV was significantly higher 
after GDM than after normoglycemic pregnancy. This 
was supported by a nonsignificant difference in the 
large-artery compliance index, C1, which indicates that 
the arteries of GDM cases were less distensible than 
those of the controls. Secondly, subclinical low-grade 
inflammation and reduced arterial compliance especially 
affected women with high BMI.
Inflammation has been shown to be a strong predictor 
of women’s cardiovascular complications [48]. We found 
that levels of TIMP-1 were significantly upregulated 
after previous GDM, reflecting low-grade inflammation 
Fig. 1 Serum concentrations of hsCRP in the four subgroups. Median 
values (minimum, maximum) of hsCRP: among obese GDM women 
2.1 (0.0, 12.4) mg/mL, obese control women 2.1 (0.3, 18.5) mg/mL, 
non‑obese GDM women 0.9 (0.0, 32.3) mg/mL, and non‑obese 
control women 0.7 (0.0, 25.7) mg/mL. Values of more than 10 mg/mL 
were measured by turbidimetric immunoassay. The overall p value is 
given at the bottom. Individual p values for pairwise comparisons are 
also presented
Fig. 2 PWV in the four subgroups. Median values (minimum, 
maximum) of PWV: among obese GDM women 6.8 (5.6, 9.7) m/s, 
obese control women 6.6 (4.8, 8.5) m/s, non‑obese GDM women 6.3 
(4.9, 9.2) m/s, and non‑obese control women 6.0 (4.5, 7.9) m/s. The 
overall p value is given at the bottom. Individual p values for pairwise 
comparisons are also presented
Fig. 3 Large (a) and small (b) artery compliance index values in 
the four subgroups. a Median values (minimum, maximum) of the 
large‑artery compliance index (C1): among obese GDM women 
13.3 (9.1, 21.8) mL/mmHg × 10, obese control women 14.7 (10.2, 
23.5) mL/mmHg × 10, non‑obese GDM women 15.2 (7.2, 25.2) mL/
mmHg × 10, and non‑obese control women 15.9 (7.5, 25.7) mL/
mmHg × 10. The overall p value is given. b Median values (minimum, 
maximum) of the small‑artery compliance index (C2): among obese 
GDM women 8.8 (2.8, 15.2) mL/mmHg × 100, obese control women 
8.6 (2.2, 17.7) mL/mmHg × 100, non‑obese GDM women 8.1 (1.8, 
17.6) mL/mmHg × 100, and non‑obese control women 8.1 (2.4, 16.0) 
mL/mmHg × 100. The overall p value is given
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among this relatively healthy and young study popula-
tion. No differences were found in circulating levels of 
MMP-8 or MMP-9 between the two study cohorts. In 
subgroup analyses, the highest levels of MMP-8 were in 
obese controls, but this did not reach statistical signifi-
cance either. A search of MEDLINE (English language; 
1989–September 2016; search terms: “MMP-8, MMP-9, 
TIMP-1” and “GDM”) revealed no publications concern-
ing female populations where levels of MMP-8, MMP-9 
or TIMP-1 have been studied in connection with previ-
ous GDM.
There is evidence that glucose can modulate the 
expression, production and activity of MMPs. For exam-
ple, endothelial cells cultured in hyperglycemic condi-
tions present increased expression and activity of MMP-9 
[49]. It is a pity that there were no samples left for MMP 
analysis taken from the patients during the period when 
they suffered from gestational diabetes. We might postu-
late, that during the pregnancy GDM increase concen-
trations of MMPs and they in turn upregulate TIMP-1. 
After the delivery, the decreasing concentrations of glu-
cose, MMPs and TIMP-1 take place consecutively. The 
prolonged upregulation of TIMP-1 found in this study 
without upregulated MMP levels may also be a result of 
the fact that upregulated TIMP-1 may suppress MMP-8 
and MMP-9 levels. Further, third explanation for pro-
longed TIMP-1 upregulation found in this work may be 
that prolonged elevation of TIMP-1 levels may mediate 
MMP-independent pro-inflammatory or growth-factor-
like signaling functions contributing to low-grade inflam-
mation [36–38].
Recent studies have reported higher CRP and hsCRP 
levels in women with a history of GDM than in age-
matched normal controls after a 1- or 5-year postpar-
tum period [4, 50, 51]. On the contrary, Ajala et al. found 
no difference in CRP in women after previous GDM 
compared to controls 4–10  years postpartum [52]. In 
our study, when hsCRP was determined on average at 
3.7 years after delivery, there was no difference between 
the age-matched study cohorts. However, low-grade 
inflammation was evident among obese women, in con-
trast to non-obese participants in subgroup analyses. The 
GDM and non-GDM women of our study did not differ 
in BMI, which can partly explain the similar hsCRP levels 
between the two study cohorts.
Only a few studies have been published concerning a 
possible relationship between PWV and previous GDM. 
Lekva et  al. reported an enhanced cardiovascular risk 
at 5-year follow-up as reflected in elevated PWV after 
previous GDM diagnosed using the old criteria of the 
World Health Organization (WHO) (OGTT: 2-h plasma 
glucose ≥7.8 mmol/L). However, they did not find such 
an association in PWV when using IADPSG diagnostic 
criteria (OGTT: fasting plasma glucose 5.1–6.9 mmol/L, 
1-h plasma glucose ≥10.0 mmol/L or 2-h plasma glucose 
8.5–11.0  mmol/L) [41, 53]. Using diagnostic criteria of 
GDM similar to those of the IADPSG [39], we observed 
a significant increase in PWV in women with previous 
GDM. Previous GDM was also a significant determinant 
of PWV in multiple linear regression analysis. Our results 
are in accordance with those of Tam et al., who reported 
higher PWV in women with a history of GDM followed 
up at a median of 6 years postpartum [54]. In contrast to 
these findings, Heitritter et al. detected no difference in 
PWV at an average of 1 year after previous GDM com-
pared with normoglycemic pregnancy [4]. There were 
no significant differences in C1 or C2 values between 
the GDM cases and controls. In a recent study, no dif-
ference was found in vascular function measured also by 
using HDI/PulseWave™CR-2000 in women with a history 
of GDM when compared to healthy controls 4–10 years 
postpartum, either [52].
Strengths of our study include the fact that we used 
standardized measurements of arterial stiffness. Deter-
mination of systemic arterial stiffness by using HDI/
PulseWave™CR-2000 equipment is widely used, and 
carotid-femoral PWV is accepted as the most reliable 
measurement of arterial stiffness [29]. We measured the 
levels of MMP-8, MMP-9 and TIMP-1 by specific immu-
noassays previously found to be suitable for diagnosis and 
monitoring of systemic low-grade inflammation associ-
ated with cardiovascular and infectious diseases as well 
as other inflammatory states [11, 13–18, 23–25]. Further, 
we performed a well characterized hospital-based study 
of two cohorts of women with a similar follow-up time 
and age. Moreover, there was no significant difference in 
BMI between the study groups, and all participants had 
undergone OGTT screening during the index pregnancy. 
Since low-risk parturients do not routinely undergo 
OGTTs in Finland [39], this last strength may also turn 
out to be a weakness, because the most low-risk women 
had to be excluded from our study [40]. Although the 
relatively short time from delivery to the follow-up study 
allowed us to observe early cardiovascular changes, it 
may be one of our study limitations as well, since major 
differences between the study groups are probably better 
observable later in their life. For example, within 7 years 
postpartum, previous GDM was identified as a risk fac-
tor of CVD by Goueslard et al. They studied database of 
more than 1.5 million deliveries and found that the inci-
dence of myocardial infarction was 0.04% in women with 
a history of GDM and 0.02% without [7].
In our subgroup analyses, obesity was associated with 
higher levels of hsCRP and higher values of PWV. We 
have earlier revealed the effect of obesity being simi-
lar with many other markers for cardio-metabolic risks 
Page 8 of 10Vilmi‑Kerälä et al. Cardiovasc Diabetol  (2017) 16:49 
among the four subgroups [40, 55]. Earlier, BMI has 
been shown to associate inversely with arterial compli-
ance [56]. As presented in Fig.  3, this seemed to be the 
case also in our study in C1 values. Surprisingly, in mul-
tiple regression analyses, BMI seemed to be protective as 
regards arterial compliance (C1 and C2). BMI was signifi-
cantly correlated with systolic blood pressure and heart 
rate (data not shown). Hence, adjusted findings concern-
ing C1 and C2 might have been affected by these rela-
tionships irrespective of possible biologic associations. 
In our opinion, this result may be explained by multiple 
interactions of C1 and C2 measurements with other con-
founding variables. This was supported by the findings of 
univariate analysis and stepwise multiple linear regres-
sion analysis without systolic BP and heart rate as covari-
ates, where inverse association between BMI and C1 was 
found and association between BMI and C2 was vanished 
(data not shown).
The prevalence of obesity is increasing around the 
world [57]. Specifically, visceral obesity modifies glucose 
and lipid metabolism. It is associated with increased risk 
of arterial stiffness and atherosclerosis both in normal-
weight subjects and patients with T2DM [58, 59]. Our 
results imply that in preventing cardiovascular risk among 
women after delivery, we need a comprehensive attitude 
in clinical care instead of concentrating on single factors.
Conclusions
When studied 3.7 years after delivery, PWV values were 
higher in women with previous GDM, indicating that 
their arteries are less distensible than those in women 
with previous normoglycemic pregnancy. Among other 
findings, this relationship was even more evident in obese 
subjects. We also found that serum levels of TIMP-1 were 
significantly upregulated after previous GDM, reflecting 
low-grade inflammation among this relatively healthy 
and young study population. Altogether, our results dem-
onstrate that previous GDM may reflect a subclinical 
inflammatory state and together with obesity may con-
tribute to an early stage of the subclinical atherosclerotic 
process even in relatively young and healthy women.
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